UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d)
of
The Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): August 12,
2020
MONOPAR
THERAPEUTICS INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-39070
|
|
32-0463781
|
(State or other
jurisdiction of incorporation)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
1000
Skokie Blvd., Suite 350, Wilmette,
IL 60091
|
|
60091
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
(847)
388-0349
Registrant’s
telephone number, including area code
N/A
(Former
name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, $0.001 par value
|
|
MNPR
|
|
The
Nasdaq Stock Market LLC
(Nasdaq Capital Market)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Indicate by check
mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§ 240.12b-2 of this chapter).
Emerging growth
company ☒
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☒
Item 7.01 Regulation FD Disclosure
On August
12, 2020, Monopar Therapeutics
Inc. (“Monopar”) issued a press release
announcing that it plans to advance the development of a
test to potentially triage COVID-19 patients into those likely
versus unlikely to progress to severe respiratory failure. The test
would use Monopar’s proprietary monoclonal antibody, ATN-658,
to detect soluble urokinase plasminogen activator receptor (suPAR)
in COVID-19 patient plasma. A suPAR test for COVID-19 patients, if
successful, could identify those at high risk for severe
respiratory failure, facilitating earlier therapeutic interventions
or allowing for the staging of patients to an optimal treatment
based on their disease characteristics.
The
press release is furnished as Exhibit 99.1 to this report and
incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
Monopar
Therapeutics Inc.
|
|
|
|
|
|
Date: August 12, 2020
|
By:
|
/s/
Kim
R. Tsuchimoto
|
|
|
|
Name: Kim
R. Tsuchimoto
|
|
|
|
Title:
Chief
Financial Officer, Secretary and Treasurer
|
|